search
Back to results

Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
ITCA 650 (exenatide in DUROS)
Sponsored by
Intarcia Therapeutics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes

Eligibility Criteria

30 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • type 2 diabetes >6 months
  • stable diet & exercise, metformin, TZD or met + TZD HbA1c >6.5% <10.0%

Exclusion Criteria:

  • prior treatment with exenatide
  • history of pancreatitis
  • history of medullary thyroid cancer or multiple endocrine neoplasia 2

Sites / Locations

  • Medpace Clinical Pharmacology Unit
  • dGd Research

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

10 mcg./day

20 mcg/day

40 mcg/day

80 mcg/day

Arm Description

ITCA 650 (exenatide in DUROS)

ITCA 650 (exenatide in DUROS)

ITCA 650 (exenatide in DUROS)

ITCA 650 (exenatide in DUROS)

Outcomes

Primary Outcome Measures

Number of Subjects With Study Drug-Related Adverse Events

Secondary Outcome Measures

To Characterize the Pharmacokinetic Profile of ITCA 650 in Subjects With Type 2 Diabetes Mellitus
Change in HbA1c from baseline
Change in Fasting Plasma Glucose (FPG) 4 Weeks From Baseline
Change in Weight From Baseline to 4 Weeks

Full Information

First Posted
February 20, 2013
Last Updated
April 5, 2013
Sponsor
Intarcia Therapeutics
search

1. Study Identification

Unique Protocol Identification Number
NCT01798264
Brief Title
Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes
Official Title
A Phase Ib, Randomized, Open-Label, Multi-Center, 4-Week Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITCA 650 in Subjects With Type 2 Diabetes Mellitus
Study Type
Interventional

2. Study Status

Record Verification Date
April 2013
Overall Recruitment Status
Completed
Study Start Date
February 2009 (undefined)
Primary Completion Date
May 2009 (Actual)
Study Completion Date
May 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Intarcia Therapeutics

4. Oversight

5. Study Description

Brief Summary
evaluate the safety and tolerability of ITCA 650 in subjects with type 2 diabetes mellitus.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
44 (Actual)

8. Arms, Groups, and Interventions

Arm Title
10 mcg./day
Arm Type
Experimental
Arm Description
ITCA 650 (exenatide in DUROS)
Arm Title
20 mcg/day
Arm Type
Experimental
Arm Description
ITCA 650 (exenatide in DUROS)
Arm Title
40 mcg/day
Arm Type
Experimental
Arm Description
ITCA 650 (exenatide in DUROS)
Arm Title
80 mcg/day
Arm Type
Experimental
Arm Description
ITCA 650 (exenatide in DUROS)
Intervention Type
Drug
Intervention Name(s)
ITCA 650 (exenatide in DUROS)
Primary Outcome Measure Information:
Title
Number of Subjects With Study Drug-Related Adverse Events
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
To Characterize the Pharmacokinetic Profile of ITCA 650 in Subjects With Type 2 Diabetes Mellitus
Description
Change in HbA1c from baseline
Time Frame
4 weeks
Title
Change in Fasting Plasma Glucose (FPG) 4 Weeks From Baseline
Time Frame
4 weeks
Title
Change in Weight From Baseline to 4 Weeks
Time Frame
4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: type 2 diabetes >6 months stable diet & exercise, metformin, TZD or met + TZD HbA1c >6.5% <10.0% Exclusion Criteria: prior treatment with exenatide history of pancreatitis history of medullary thyroid cancer or multiple endocrine neoplasia 2
Facility Information:
City
Miami Gardens
State/Province
Florida
ZIP/Postal Code
33169
Country
United States
Facility Name
Medpace Clinical Pharmacology Unit
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45212
Country
United States
Facility Name
dGd Research
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
23578605
Citation
Henry RR, Logan D, Alessi T, Baron MA. A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes. Clin Ther. 2013 May;35(5):634-645.e1. doi: 10.1016/j.clinthera.2013.03.011. Epub 2013 Apr 8.
Results Reference
derived

Learn more about this trial

Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes

We'll reach out to this number within 24 hrs